How Long For Hcg To Work Trt
Transl Androl Urol. 2018 Jul; vii(Suppl 3): S348–S352.
Indications for the use of human being chorionic gonadotropic hormone for the management of infertility in hypogonadal men
Received 2018 Jan 17; Accepted 2018 Apr 9.
Abstract
Hypogonadism amid men desiring fertility preservation presents a unique challenge to physicians. Over the past decade the number of younger men with hypogonadism has increased dramatically. These men are often treated with testosterone replacement therapy (TRT) which can upshot in azoospermia and potentially infertility. Man chorionic gonadotropin (hCG) therapy can assistance re-establish or maintain spermatogenesis in hypogonadal men. Nosotros review the indications, and hash out the current evidence for the office of hCG in men with hypogonadisms.
Keywords: Human chorionic gonadotropin (hCG), hypogonadism, testosterone replacement therapy (TRT), hypogonadal hypogonadism, anabolic androgenic steroids (AAS), infertility
Introduction
The importance of the therapeutic human being chorionic gonadotropin (hCG) treatment has grown tremendously over the last couple decades due to an exponential increment in the prevalence of hypogonadism in younger men and the employ of anabolic androgenic steroids (AAS). From 2001 to 2011 men on testosterone replacement therapy (TRT) increased 3 fold overall and 4 times more amid men aged twoscore–49 (ane). The overall prevalence of hypogonadism in American men is 7% in men younger than 40 years and 38% in men over the age of 45 (2,3). The use of AAS has been institute to be as loftier as 3 meg amongst American men (iii) and accept a life fourth dimension of prevalence utilise of iii.0% to 4.ii% (four). This increase has occurred along with steady increase in historic period of paternity (five) creating an evolving challenge of treating hypogonadism and preserving fertility.
Luteinizing hormone (LH) in the male is produced by the anterior pituitary in response to pulsatile secretion of gonadotropic releasing hormone (GnRH) from the hypothalamus. It acts on Leydig cells in the testicles promoting the production of testosterone. In men with hypogonadotropic hypogonadism (HH), or men with decreased LH secondary to exogenous testosterone utilise, the lack of LH results in severely decreased intratesticular testosterone levels. Without intratesticular testosterone spermatogenesis is impaired, and by replacing lost LH production with hCG, spermatogenesis can be restored by restoring adequate levels of intratesticular testosterone.
hCG has as well found a prominent role in treating endocrine failure of the testicle in men with anabolic steroid induced hypogonadism. These men take lost the ability to produce their ain testosterone and hCG has been indicated as a part of an algorithm to help recover endogenous testosterone production (six).
Finally, hCG has besides been used to reduce some of the side effects of TRT, mainly preventing testicular atrophy and helping maintain response to TRT by "cycling off" TRT with a periodic replacement of therapy with hCG.
Pharmacology of hCG
hCG nigh prominent function in physiology is in that of maintaining early pregnancy. It is named from the Latin discussion chordata, meaning after birth, since information technology is primarily produced past the placenta. The starting time recognition of hCG as a gonadotropin was observed when human placental tissue was transplanted in rabbits and induced ovulation (vii-9).
hCG is a hormone comprising of an α and a β-subunit. hCG and LH share an identical α-subunit. hCG differs from LH in that its β-subunit has a highly glycosylated 24 amino acrid tail. The side chain increases the receptor action and slows the metabolism of hCG every bit compared to LH. This results in a half-life of 36 hours for hCG compared to xxx minutes for LH. The characteristics of sharing a receptor, having increased receptor activity, and a longer half-life make hCG an platonic pharmacological analog to LH.
Indications for hCG in combination with TRT
Preserving spermatogenesis with TRT
Exogenous steroid use impairs spermatogenesis by promoting negative feedback on both the hypothalamus and pituitary gland. This reduces the pulsatile secretion of GnRH and LH respectively. The loss of LH secretion shuts downward the production of testosterone by Leydig cells which in turn significantly reduces intratesticular testosterone levels. This altering of the hypothalamus-pituitary-gonadal (HPG) axis and drop of intratesticular testosterone tin can lead to azoospermia within x weeks of starting TRT (10). Even more alarming is the fact that up to 10% of men tin remain azoospermic later the cessation of TRT.
hCG therapy can help preserve spermatogenesis in men undergoing TRT by maintaining intratesticular testosterone levels. Information technology was has been shown that follicle stimulating hormone (FSH) lonely cannot initiate or maintain spermatogenesis in hypogonadal (eleven) men leading to the discovery of the importance of intratesticular testosterone in spermatogenesis. In healthy eugonadal men selected to undergo TRT information technology was shown that their intratesticular testosterone levels dropped past 94%. However, in those who received 250 IU SC every other day along with TRT their intratesticular testosterone levels only dropped seven%. Additionally, in men who received TRT and 500 IU of hCG every other mean solar day an increase in intratesticular testosterone by 26% was observed (12). This proved that co-administering low dose hCG could maintain intratesticular testosterone in those undergoing TRT. It was subsequently shown that not only is intratesticular testosterone increased with co-assistants hCG but spermatogenesis is preserved besides at i yr follow up (13). These studies proved that by concomitant hCG assistants with TRT spermatogenesis and thus potentially fertility could be preserved.
Based off this evidence an algorithm was suggested for the simultaneous treatment of hypogonadism and preservation of fertility (fourteen). All men wishing to preserve fertility while on TRT should have a baseline semen analysis (SA). Side by side it is important to determine the appropriate dosing regimen of hCG based off the timeline for desired pregnancy. For men who wish to obtain pregnancy within six months it was suggested to discontinue TRT and start iii,000 IU of hCG intramuscular, or subcutaneous every other day. SA should so be performed every two months. Clomiphene citrate 25–l mg PO daily tin be added or omitted to promote FSH production (15). We advise including of clomiphene citrate in all men who are already oligospermic or azoospermic. Information technology tin be omitted in men who are initiating TRT and hCG simultaneously and take normal semen parameters.
If Semen parameters fail to meliorate and FSH remains depression, Gonal-f (recombinant FSH) 75 IU every other day can be added. In men who desire pregnancy within 6–12 months TRT can be continued with co-administration of 500 IU of HCG every other day ± clomiphene citrate can be used. When planning for pregnancy in greater than 12 months TRT should exist cycled off every vi months replaced past a iv-week bicycle of 3,000 IU of hCG every other day. For men who do not want to preserve fertility testicular size can me maintained while undergoing TRT with 1,500 IU of HCG given weekly. Which is enough to maintain pre-TRT levels of intratesticular Testosterone (11). Tabular array one summarizes recommendations for preserving spermatogenesis in men on TRT (xvi).
Table 1
Summary of recommendations for maintenance of spermatogenesis with TRT or AAS use
| Timing of desired pregnancy | Treatment recommendation |
|---|---|
| <half-dozen months | Stop TRT/AAS |
| Starting time three,000 IU hCG every other day ± clomiphene citrate 25 mg oral daily | |
| Semen assay every 2 months | |
| No FSH response: discontinue clomiphene and add rhFSH 75 IU every other twenty-four hours | |
| 6–12 months | Go along TRT |
| Start 500 IU hCG every other mean solar day ± clomiphene citrate 25 mg oral daily | |
| >12 months | Continue TRT |
| Cycle off TRT/AAS every 6 months with a 4-week cycle of 3,000 IU hCG every other mean solar day |
TRT, testosterone replacement therapy; AAS, anabolic androgenic steroids; hCG, human chorionic gonadotropin; FSH, follicle stimulating hormone; rhFSH, recombinant human FSH.
Use of hCG for recovery of spermatogenesis in men using anabolic steroids
While spontaneous recovery of spermatogenesis can occur with the cessation of TRT or AAS use lonely, it tin take several months to years. Median times for spermatogenesis to recover to thresholds of twenty, 10, and 3 one thousand thousand per mL were 3.4, 3.0 and 2.five months respectively. Sixty-seven percentage of men recovered to a sperm concentrations of xx million per mL within half dozen months still some men took upwardly to 2 years (17). The length of fourth dimension to recovery of spermatogenesis is often too long for many patients who desire fertility. For these men hCG based treatments have been used to induce spermatogenesis sooner. A review performed showed that well-nigh treatment regimens consist of starting with hCG just doses of 1,500 to five,000 IU 2–3 times per week for three to six months and then adding recombinant FSH in doses of 75 to 400 IUs 2–3 times per calendar week in men who did not regain spermatogenesis on hCG alone (18). Specifically, a multi-institutional study showed that azoospermic or severely oligospermic men who had previously used TRT and treated with hCG iii,000 IU every other day supplemented with either anastrozole, clomiphene citrate, FSH or tamoxifen were able to regain spermatogenesis to a concentration of 22 million per mL with mean time of 4 months (15).
A proposed algorithm consists of stopping testosterone use and obtaining baseline SA, and hormones (FSH, LH, T, estradiol). It is important to consider cryopreservation at any point the patient is found to have improved to oligospermic counts during treatment. Treatment should be initiated with hCG 2,000 IU every other twenty-four hours and clomiphene citrate 50 mg PO every other day. Later on iii months SA and hormones should be repeated. If estradiol is high, then anastrozole 1 mg PO twice weekly tin can be added. If azoospermia or severe oligospermia persist and so FSH 75 IU every other day should be added. If the next SA at 3 months has persistent azoospermia, then testicular sperm extraction (TESE)/micro TESE should exist considered. Figure 1 contains a summary of recommendations for initiating spermatogenesis in men using AAS or TRT (16).
Algorithm for the treatment of steroid induced infertility. SA, semen assay; T, testosterone; LH, luteinizing hormone; FSH, follicle stimulating hormone; hCG, human chorionic gonadotropin; TESE, testicular sperm extraction.
Use of hCG in men with HH
HH tin be caused by built GnRH deficiency that can exist classified as Kallmann's syndrome and normosmic idiopathic hypogonadotropic hypogonadism (IHH). HH occurs with an estimated prevalence that ranges from one:10,000 to one:86,000 individuals (19). Rarely HH can exist caused past hemochromatosis, and sarcoidosis of the pituitary, or other lesions to the HPG axis. These lesions include pituitary adenomas and other cardinal nervous system tumors. While less prevalent, the impact of hCG therapy is simply as great, every bit these men were one time accounted infertile and at present tin can regain spermatogenesis with hCG therapy.
While HH is far less common these men can successfully regain fertility with treatments similar to that for hypogonadal men. Formerly GnRH infusion pumps were used to evangelize a pulsatile release of GnRH. This method of therapy has fallen out of favor primarily due to cost and the inconvenience of having to wear a pump. Also this blazon of therapy requires a functioning pituitary on which GnRH tin act and therefore it will only exist helpful in men who take HH secondary to hypothalamic failure only. This has resulted in the principal utilise of gonadotropins to treat infertility in men with HH as it has been shown to induce spermatogenesis (20). The regimens used to treat men with HH unremarkably consist of hCG 1,500–2,000 IU 2–3 times weekly to achieve at testosterone level within the normal range. If this lonely fails to induce spermatogenesis within 4–6 months FSH 75 IU SC every other solar day can be added (21). It is important to annotation that information technology can take up to 2 years on this regimen to accomplish maximum sperm production. Factors that can predict college rate of response to therapy include larger baseline testicular size, postpubertal onset of HH, and low torso mass index (19). An important omission in the treatment of men with HH is to non utilize clomiphene citrate as it will have no effect with non-operation hypothalamus.
Employ of hCG to promote spermatogenesis in men with infertility
hCG as well has been shown to accept a role in hormonally optimizing men with non-obstructive azoospermia to amend sperm retrieval. A multicenter report demonstrated that increasing FSH by 1.5 times it initial level and testosterone to 600–800 ng/dL increased chances of sperm in the ejaculate or in sperm retrieval at the time of TESE. Patients were treated with clomiphene citrate, and in men who did non have increased LH or testosterone levels hCG was added to their treatment regimen at a dose of 5,000 IU weekly. Men who failed to have an increase in FSH were also given human menopausal hormone. Overall 11% men were able to have sperm in the ejaculate and the rate of successful sperm retrieval with TESE was 57% compared to 33.6% in not-medically treated controls (22).
Similarly, sperm retrieval in men with not-mosaic Klinefelter's syndrome and hypogonadism is more successful with medical therapy to treat hypogonadism (23). Men with non-mosaic Klinefelter's syndrome with testosterone levels less than 250 and that responded to medical therapy with either clomiphene citrate, aromatase, or hCG had 77% sperm retrieval rate during testicular microdissection compared to 55% in men who did not answer.
Conclusions
Equally the age of men with hypogonadism continues to decrease and the age of paternity continues to increase more men will need to handling for hypogonadism while maintaining fertility. hCG is a rubber and efficacious alternative or offshoot to TRT in men desiring to preserve fertility while treating their hypogonadism. hCG can also be used help restore spermatogenesis in men hypogonadal hypogonadism or steroid induced harm of spermatogenesis.
Acknowledgements
Figures reprinted/adapted past permission from Springer Nature. Terms and Conditions for RightsLink Permissions Springer Customer Service Heart GmbH: Springer Nature, The Complete Guide to Male Fertility Preservation past Ahmad Majzoub and Ashok Agarwal, Chapter ix, Fertility Preservation in Hypogonadal Men by Robert J. Carrasquillo and Ranjith Ramasamy 2017.
Footnotes
Conflicts of Interest: The authors have no conflicts of interest to declare.
References
one. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the U.s.a., 2001 to 2011. JAMA Intern Med 2013;173:1465-6. ten.1001/jamainternmed.2013.6895 [PMC costless article] [PubMed] [CrossRef] [Google Scholar]
2. Rohrmann S, Platz EA, Selvin Due east, et al. The prevalence of low sex activity steroid hormone concentrations in men in the 3rd National Health and Nutrition Examination Survey (NHANES Iii). Clin Endocrinol (Oxf) 2011;75:232-ix. x.1111/j.1365-2265.2011.04043.10 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
three. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762-9. 10.1111/j.1742-1241.2006.00992.ten [PMC complimentary article] [PubMed] [CrossRef] [Google Scholar]
4. Fronczak CM, Kim ED, Barqawi AB. The insults of illicit drug apply on male fertility. J Androl 2012;33:515-28. 10.2164/jandrol.110.011874 [PubMed] [CrossRef] [Google Scholar]
5. Kovac JR, Addai J, Smith RP, et al. The effects of advanced paternal age on fertility. Asian J Androl 2013;fifteen:723-8. ten.1038/aja.2013.92 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and handling. Fertil Steril 2014;101:1271-9. 10.1016/j.fertnstert.2014.02.002 [PubMed] [CrossRef] [Google Scholar]
7. Aschner B. Ueber die function der hypophyse. Pflug Curvation Gest Phsiol 1912;146:one-147. 10.1007/BF01681114 [CrossRef] [Google Scholar]
eight. Fellner OO. Experimentelle untersuchungen über dice wirkung von gewebsextrakten aus der Plazenta und den weiblichen Sexualorganen auf das Genitale. Arch Gynakal 1913:100:641 ten.1007/BF01702558 [CrossRef] [Google Scholar]
9. Hilrose T. Experimnetelle histologische studie zure genese corpus luteum. Mitt Med Fakultd Unive ZU 1919;23:63-lxx. [Google Scholar]
10. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Wellness Organisation Task Force on methods for the regulation of male person fertility. Lancet 1990;336:955-9. 10.1016/0140-6736(90)92416-F [PubMed] [CrossRef] [Google Scholar]
eleven. Schaison M, Young J, Pholsena M, et al. Failure of combined follicle-stimulating hormone-testosterone assistants to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1993;77:1545-9. [PubMed] [Google Scholar]
12. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab 2005;90:2595-602. x.1210/jc.2004-0802 [PubMed] [CrossRef] [Google Scholar]
13. Hsieh TC, Pastuszak AW, Hwang G, et al. Concomitant intramuscular homo chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013;189:647-50. 10.1016/j.juro.2012.09.043 [PubMed] [CrossRef] [Google Scholar]
xiv. Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian J Androl 2015;17:197-200. 10.4103/1008-682X.142772 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Wenker EP, Dupree JM, Langille GM, et al. The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use. J Sex activity Med 2015;12:1334-vii. ten.1111/jsm.12890 [PubMed] [CrossRef] [Google Scholar]
16. Carrasquillo R, Ramasamy R. Fertility Preservation in Hypogonadal Men. In: Majzoub A, Agarwal A. editors. The Complete Guide to Male Fertility Preservation. Springer Nature, 2017:105-21. [Google Scholar]
17. Liu PY, Swerdloff RS, Christenson PD, et al. Rate, extent, and modifiers of spermatogenic recovery afterward hormonal male contraception: an integrated assay. Lancet 2006;367:1412-20. x.1016/S0140-6736(06)68614-v [PubMed] [CrossRef] [Google Scholar]
18. McBride JA, Coward RM. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid utilise. Asian J Androl 2016;18:373-80. 10.4103/1008-682X.173938 [PMC gratis article] [PubMed] [CrossRef] [Google Scholar]
19. Hayes FJ, Seminara SB, Crowley WF., Jr Hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am 1998;27:739-63, vii. ten.1016/S0889-8529(05)70039-6 [PubMed] [CrossRef] [Google Scholar]
20. Sokol RZ. Endocrinology of male infertility: evaluation and treatment. Semin Reprod Med 2009;27:149-58. 10.1055/due south-0029-1202303 [PubMed] [CrossRef] [Google Scholar]
21. Warne DW, Decosterd G, Okada H, et al. A combined analysis of information to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant homo follicle-stimulating hormone and human chorionic gonadotropin. Fertil Steril 2009;92:594-604. ten.1016/j.fertnstert.2008.07.1720 [PubMed] [CrossRef] [Google Scholar]
22. Hussein A, Ozgok Y, Ross L, et al. Optimization of spermatogenesis-regulating hormones in patients with non-obstructive azoospermia and its bear on on sperm retrieval: a multicentre study. BJU Int 2013;111:E110-4. ten.1111/j.1464-410X.2012.11485.10 [PubMed] [CrossRef] [Google Scholar]
23. Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter'due south syndrome. J Urol 2009;182:1108-xiii. x.1016/j.juro.2009.05.019 [PubMed] [CrossRef] [Google Scholar]
Articles from Translational Andrology and Urology are provided hither courtesy of AME Publications
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087849/
0 Response to "How Long For Hcg To Work Trt"
Post a Comment